Identify underlying allergy aetiology

Article

Search for common clues to complicating factors, including blephartis and dry eye

Aplethora of effective antihistamines does little to relieve ocular allergies when complicated by other concomitant factors, said Dr Michael B. Raizman, at the 29th annual Current Concepts in Ophthalmology conference held in association with the Wilmer Eye Institute.

"You would think allergy would be easy to treat," said Dr Raizman, associate professor of ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, USA. "We have the best antihistamines in the world. They are incredibly effective, yet our patients still come in complaining. They've tried everything, and nothing is working. Why is that?"

Obvious allergic conjunctivitis

This condition is seasonal and caused by pollens in the air. Patients may complain that the overthecounter (OTC) eye drops they use no longer work, Dr Raizman said. The most common reason for this type of failure for allergy treatment is the presence of other conditions of the ocular surface.

"[More than] 75% of treatment failures are caused by either dry eye or blepharitis," he said.

"You must treat the allergy and the under­lying dry eye or blepharitis as well," Dr Raizman said. "Sometimes, many patients can have all three of these - to varying degrees."

The presence of dry eye may not always be obvious. In such cases, lissamine green staining and rose bengal staining are often useful.

"Try to think of all three together, and treat all of them," he said. "Patients may be describing what sound to you like allergies. You can treat their allergies all you want, but if their blepharitis is bothering them, they will view the allergy treatment as a failure."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
© 2025 MJH Life Sciences

All rights reserved.